AFRRI

ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome

Retrieved on: 
Thursday, March 28, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Radiation, Acute radiation syndrome, Attack, ARS, Inflammation, Education, Chronic obstructive pulmonary disease, RNCP, USUHS, Virus, IND, European Medicines Agency, Outline of health sciences, Nausea, Accident, Hypoxia (medical), NIAID, Defense Threat Reduction Agency, AFRRI, HIE, Vaccine, Collection, Vomiting, Food, FDA, Defense, Infection, Peptide, Pharmaceutical industry

“We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.

Key Points: 
  • “We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.
  • AFRRI is unique and powerful radiobiological research institute, with six decades of active, robust, and outstanding support to the U.S. Department of Defense through research, reach-back, and education.
  • It is the only U. S. Department of Defense medical R&D facility dedicated solely to nuclear and radiological defense.
  • ReAlta Life Sciences, Inc. is a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life threatening acute inflammatory and rare diseases.

Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Retrieved on: 
Wednesday, February 28, 2024
Infection, Therapy, Bangladesh Technical Education Board, Parity, AFRRI, USUHS, Cocaine, Medicine, NIAID, NIH, Bar-Ilan University, PLUR, World War II, FDA, PLX, Partnership, 3D, Food, Ageing, GMP, Hope, BIRAD, Plural, Meat, Risk, Outline of health sciences, CDMO, Climate, Climate change, Health, Water, Food and Drug Administration, Coffee, Knowledge, Agriculture, Food security, Negotiation, Good manufacturing practice, Pharmaceutical industry

Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.

Key Points: 
  • Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.
  • We also estimate that our innovative new production process will reduce the amount of growing area by 95%, potentially preventing deforestation.
  • By creating novel cell-based products both independently and through partnerships, Pluri is showing what’s possible when we all work together.
  • As such, our transformative technology is not only creating long-term value for our shareholders; it’s also making the world a better place.

U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

Retrieved on: 
Tuesday, July 11, 2023
Radiation, Depression, War, ARS, U.S. Department of Defense Strategy for Operating in Cyberspace, Marketing, Drug discovery, Survival, Uniformed Services University of the Health Sciences, Bone marrow, Power plant engineering, Infection, Pluri Inc., Cell, Plural, Bangladesh Technical Education Board, PLUR, Animal, Anemia, AFRRI, TASE, Outline of health sciences, USUHS, Orphan, NIAID, FDA, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Thrombocytopenia, NIH, Radiation exposure, Food, Medical imaging, Pharmaceutical industry, Medical device

The work specified by the contract is based on communications with the FDA and will enable Pluri to make significant progress toward marketing approval for PLX-R18.

Key Points: 
  • The work specified by the contract is based on communications with the FDA and will enable Pluri to make significant progress toward marketing approval for PLX-R18.
  • PLX-R18 is developed with the intention of being eligible for purchase by the U.S. Strategic National Stockpile as a medical countermeasure for exposure to nuclear radiation, following FDA approval.
  • H-ARS is a deadly disease that can result from nuclear disasters and radiation exposure.
  • Additionally, PLX-R18 was tested in humans with incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT) and was well tolerated with a favorable safety profile.

Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications

Retrieved on: 
Monday, August 8, 2022
Science, Stem Cells, Other Science, Biotechnology, Research, Health, Clinical Trials, Other Health, Death, Risk, Uniformed Services University of the Health Sciences, Vasculitis, Inflammation, Private Securities Litigation Reform Act, SEC, Bleeding, Clinical trial, Regenerative medicine, Policy, Annual report, Research, Department, Patient, AFRRI, Bone marrow, Company, Twitter, Department of Defense Serum Repository, Radiation, Dehydration, Partnership, Syndrome, Outline of health sciences, Edema, Acute radiation syndrome, Survivor, Social media, Infection, Investor, LinkedIn, ARS, Time, GI, Pharmaceutical industry, Facebook

ARS may be associated with destructive and irreparable changes in the bone marrow and gastrointestinal (GI) tract, resulting in infection, hemorrhage and dehydration.

Key Points: 
  • ARS may be associated with destructive and irreparable changes in the bone marrow and gastrointestinal (GI) tract, resulting in infection, hemorrhage and dehydration.
  • At lower doses a period of bone marrow damage lasting weeks which ultimately can be lethal without intervention is expected.
  • Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization.
  • MultiStem therapys potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit.